Anthropic, the AI company behind the Claude chatbot, plans to allocate 5% of its shares to a new public benefit fund, with potential increases tied to its valuation. The fund aims to support public benefit projects beyond current research and partnerships, focusing on social impacts of AI like employment disruption. The company has already committed $200 million to study AI's economic effects and plans to provide more details on the fund's governance soon. This initiative, combined with founder and employee equity pledges, could dedicate about 20% of shares to public benefit causes.
Anthropic's commitment of 5% of its shares to a public benefit fund provides context for readers interested in AI and technology. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 19, 2026 20:51 WIB: out of 150 priced US tech stocks tradable on Pluang, 106 rose and 39 fell today. Notable movers include Western Digital Corp (WDC) with a price of USD 353.39 and a 1-day change of +6.44%, Intel Corp (INTC) at USD 94.61 with +5.30%, and Iris Energy Limited (IREN) at USD 28.38 with +5.15%.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
